Overview

A Study to Evaluate the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-079 in Combination With Standard Background Therapy in Participants With Moderate to Severe Systemic Lupus Erythematosus (SLE)

Status:
Completed
Trial end date:
2021-11-04
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of TAK-079 in comparison with matching placebo, administered once every 3 weeks over a 12-week dosing period in participants with active SLE who are receiving stable background therapy for SLE.
Phase:
Phase 1
Details
Lead Sponsor:
Millennium Pharmaceuticals, Inc.